Poolbeg Pharma (LON:POLB) Stock Price Down 3.2% – Here’s What Happened

Posted by Donna Armstrong on Jan 24th, 2026

Shares of Poolbeg Pharma PLC (LON:POLB – Get Free Report) were down 3.2% on Thursday . The stock traded as low as GBX 4.30 and last traded at GBX 4.50. Approximately 1,183,818 shares were traded during mid-day trading, a decline of 7% from the average daily volume of 1,268,475 shares. The stock had previously closed at GBX 4.65.

Wall Street Analysts Forecast Growth

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, November 20th.

Read Our Latest Stock Report on POLB

Poolbeg Pharma Price Performance

The firm has a 50-day moving average of GBX 4.08 and a 200-day moving average of GBX 3.66. The stock has a market cap of £31.37 million, a PE ratio of -3.95 and a beta of 2.11.

About Poolbeg Pharma

(Get Free Report)

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.